SCHEMBL4131563

SCHEMBL4131563

O=C(O)NCCc1cc(-c2cccnc2F)c(Br)s1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NAPRT Q6XQN6 1/20 0.35
LIPG Q9Y5X9 3/20 0.34
CYP1A2 P05177 1/20 0.34
CHRM4 P08173 1/20 0.34
CYP2D6 P10635 1/20 0.34
LIPC P11150 1/20 0.34
DHODH Q02127 4/20 0.33
GSK3B P49841 1/20 0.33
DYRK1A Q13627 1/20 0.33
TDP2 O95551 1/20 0.32
G6PD P11413 1/20 0.32
S100A4 P26447 1/20 0.32
ROCK2 O75116 1/20 0.32
MEN1 O00255 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
KMT2A Q03164 1/20 0.31
PIP4K2A P48426 1/20 0.31
PIP4K2C Q8TBX8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4125114 0.81 NPC1 (0.32) LIPGCYP1A2CHRM4CYP2D6LIPC
SCHEMBL4125903 0.81 NAMPT (0.38) LIPGLIPCPIP4K2APIP4K2C
SCHEMBL4118036 0.81 DHODH (0.36) NAPRTLIPGCYP1A2CHRM4CYP2D6
SCHEMBL4132234 0.80 ATM (0.38) LIPGLIPCNPC1RAB9APIP4K2A
SCHEMBL4119129 0.80 DYRK1A (0.33) NAPRTLIPGCYP1A2CHRM4CYP2D6
SCHEMBL3799055 0.80 ALDH1A1 (0.36) CYP2D6MEN1NPC1RAB9AKMT2A
SCHEMBL4130804 0.79 MGAM (0.35) GSK3BDYRK1AMEN1NPC1RAB9A
SCHEMBL4117665 0.79 LIPG (0.34) LIPGLIPCPIP4K2APIP4K2C
SCHEMBL4127371 0.79 MAOA (0.35) LIPGLIPCMEN1KMT2A
SCHEMBL4131197 0.78 DYRK1A (0.33) LIPGCYP1A2CHRM4CYP2D6LIPC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2190822-B1 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2014-12-31 EP disclosed
US-20090156642-A1 5-Membered heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156642-A1 5-Membered heterocyclic compound CEL, PGA5, COG5 NAPRT 2758/4885LIPG 2467/4885CYP1A2 539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.